Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Hits after hits on Small Caps

<< Previous

Bullboard Posts

Next >>

Comment by drewmumawon Sep 18, 2024 10:18am

90 Views

Post# 36228841

RE:RE:RE:RE:RE:RE:RE:Hits after hits on Small Caps

I wasn't on the call, unfortunately, so that's why I was asking.

There's an interview with the Moberg CEO on Redeye, but it's in Swedish.
https://www.redeye.se/research/1039785/moberg-pharma-intervju-med-vd-anna-ljung-5

It sounds like there's still a glimmer of hope:
https://www.redeye.se/research/1039689/moberg-pharma-stuck-between-a-rock-and-a-hard-place

It is also important to note that even if the uncertainty of the ongoing North American study has increased substantially, there is very little information on which to base an informed decision. It could still turn out that the study is acceptable to be able to file with the FDA.

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3